News

Bayer decides to withdraw cholesterol lowering drug

BMJ 2001; 323 doi: 10.1136/bmj.323.7309.359/a (Published 18 August 2001)
Cite this as: BMJ 2001;323:359.2

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Fred Charatan
  1. Florida

    Cerivastatin (Baycol in the United States, Lipobay in the United Kingdom), a cholesterol lowering drug made by Bayer Corporation and initially approved in the US in 1997, has been withdrawn by the manufacturer. There have been 31 deaths in the US from severe rhabdomyolysis in patients taking the drug. Twelve patients were taking concomitant gemfibrozil, which lowers blood concentration of triglycerides.

    Rhabdomyolysis, a serious and potentially fatal adverse effect of …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular